Natera announces allocation of $1,000,000 to Signatera Research Fund for initiatives that focus on using Signatera to develop or refine specific and defined medical knowledge.
On April 20th, 2021
Signatera Research Fund
Natera supports independent research and education initiatives from the global healthcare community that align with Natera’s medical and scientific strategy for improving patient outcomes in areas of unmet medical need. This year, Natera has allocated $1,000,000 for research initiatives that are focused on using Signatera to develop or refine specific and defined medical knowledge. More information can be found here: natera.com/signatera-research-fund
Application selection criteria
All eligible applications (including all cancer types) will be considered. Winning proposals should meet the following criteria:
• Providers must practice within the United States.
• Treatment-response monitoring of molecular residual disease (MRD) in colorectal cancer I and IV, including oligometastatic and other gastrointestinal malignancies in the neoadjuvant or adjuvant settings, uses Signatera to escalate or de-escalate treatment.
• The study has access to both tumor tissue and blood or plasma samples.
• The proposal presents a novel idea for using Signatera to answer a clinical question.
In addition:
• Natera will continue to accept submissions focused on treatment-response monitoring of molecular residual disease (MRD) in ovarian (post-surgical or post-chemotherapy), breast (HER2+, TNBC in the neoadjuvant setting), and muscle invasive bladder cancer (adjuvant or neoadjuvant settings).
• Preference will be given to prospective proposals matched with defined clinical outcomes. Proposals incorporating Altera, a tumor genomic profile, will also be considered.
How to apply
• Initiative requests must be submitted to Natera using the online application form.
• Once the application is submitted, a confirmation email will be sent verifying that the application has been received.
• The deadline for application submissions is July 2, 2021, at 11:59 pm (PST).
The review process
• Natera’s initiative committee will review each application.
– If the research proposal fits the program, Natera will contact the applicant to request further information regarding the full extent of the research.
• Natera will perform due diligence.
– Final application decisions will be announced on August 23, 2021
.- All requests will be reviewed for compliance in meeting Natera’s policies for initiative funding.
– Those awarded funding will be contacted regarding next steps, including starting the initiative process.
– Initiative start is subject to the award recipient’s acceptance of Natera’s terms and conditions, which will be provided to recipients.
If you have any questions about this initiative, please contact your MSL or email us at signateragrants@natera.com.
TO APPLY, GO TO: natera.com/signatera-research-fund
Signatera Research Fund
Natera supports independent research and education initiatives from the global healthcare community that align with Natera’s medical and scientific strategy for improving patient outcomes in areas of unmet medical need. This year, Natera has allocated $1,000,000 for research initiatives that are focused on using Signatera to develop or refine specific and defined medical knowledge. More information can be found here: natera.com/signatera-research-fund
Application selection criteria
All eligible applications (including all cancer types) will be considered. Winning proposals should meet the following criteria:
• Providers must practice within the United States.
• Treatment-response monitoring of molecular residual disease (MRD) in colorectal cancer I and IV, including oligometastatic and other gastrointestinal malignancies in the neoadjuvant or adjuvant settings, uses Signatera to escalate or de-escalate treatment.
• The study has access to both tumor tissue and blood or plasma samples.
• The proposal presents a novel idea for using Signatera to answer a clinical question.
In addition:
• Natera will continue to accept submissions focused on treatment-response monitoring of molecular residual disease (MRD) in ovarian (post-surgical or post-chemotherapy), breast (HER2+, TNBC in the neoadjuvant setting), and muscle invasive bladder cancer (adjuvant or neoadjuvant settings).
• Preference will be given to prospective proposals matched with defined clinical outcomes. Proposals incorporating Altera, a tumor genomic profile, will also be considered.
How to apply
• Initiative requests must be submitted to Natera using the online application form.
• Once the application is submitted, a confirmation email will be sent verifying that the application has been received.
• The deadline for application submissions is July 2, 2021, at 11:59 pm (PST).
The review process
• Natera’s initiative committee will review each application.
– If the research proposal fits the program, Natera will contact the applicant to request further information regarding the full extent of the research.
• Natera will perform due diligence.
– Final application decisions will be announced on August 23, 2021
.- All requests will be reviewed for compliance in meeting Natera’s policies for initiative funding.
– Those awarded funding will be contacted regarding next steps, including starting the initiative process.
– Initiative start is subject to the award recipient’s acceptance of Natera’s terms and conditions, which will be provided to recipients.
If you have any questions about this initiative, please contact your MSL or email us at signateragrants@natera.com.
TO APPLY, GO TO: natera.com/signatera-research-fund
No comments have been posted yet.